By Bruce R. Blazar, Patricia A. Taylor, and Daniel A. Vallera To determine if in utero transplantation could restore the immune system of mice with a severe combined immunodeficiency (SCID) disorder, C57BL/GS~-scid/scid fetuses were injected on day 14/15 of gestation with adult congenic donor bone marrow (BM) cells. Congenic BM engrafted in one of eight (13%) recipients. Reconstitution of both lymphoid and nonlymphoid lineages was observed. In vitro and in vivo Tcell function was documented. Stem cells were shown to have engrafted by secondary transfer studies. When fully allogeneic C57BL/6 (H-2b) or B1O.BR (H-2') adult BM cells were given to C.B-17-scidlscid (H-2d) fetal recipients, 15 of 54 (28%) recipients had evidence of engraftment, with up to 76% of peripheral blood (PB) being of in utero donor BM origin on day 131 postnatally. In all mice with persistent leukocyte engraftment, T-and B-lymphoid cells were en-T WAS OBSERVED by Owen' in 1945 that the majority of dizygotic cattle twins are chimeric at birth and have long-term retention of red cells of dizygotic origin. Such cattle are often tolerant or at least partially tolerant for organ and skin grafts from their dizygotic twin donor.'" Seminal observations by Billingham et aI8 showed that skin graft tolerance could be conferred to mice by the in utero injection of a suspension of allogeneic cells. Fleischman and Mintz' first demonstrated that a congenital hematopoietic defect could be corrected by the in utero injection of nondefective hematopoietic cells. Flake et all0 have shown that hematopoietic engraftment can be obtained in larger animals (sheep) with a nondefective hematopoietic system that were injected in utero. These and other studies served as the basis for attempts by other investigators to replace in whole or in part the lymphohematopoietic system by in utero transplanta-
tion. I '
The primary targets of initial human clinical trials of in utero transplantation were recipients with underlying immunodeficiency disorders. Although detailed information on the immune reconstitution of animals given lymphohematopoietic cells in utero is generally lacking in the literature, in utero injection of lymphohematopoietic cells into pigs,'' rabbit^,'^ and ratsI4 resulted in skin graft acceptance, suggesting that at least a low level of chimerism could be induced by this approach. The first successful in utero transplant, performed by Touraine et al,I5-l7 was for a patient with severe combined immunodeficiency disorder (SCID) characterized by the lack of major histocompatibility complex (MHC) class I1 antigens on lymphocytes (known as the bare lymphocyte syndrome). After several different infusions of lymphohematopoietic cells in utero and postnatally, 26% of peripheral blood (PB) lymphocytes were of in utero origin. T-cell reconstitution in this patient has been reported to be virtually complete, immunoglobulin levels were reportedly relatively low,I6 and the child, at last report," was alive, healthy, and receiving immunoglobulin replacement therapy. In one of two other fetuses with SCID syndromes, there was no evidence of engraftment detected 4 weeks after the intravenous and intraperitoneal infusion of T cell-depleted maternal bone marrow
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Blood, Vol 86, No 11 (December l), 1995 pp [4353] [4354] [4355] [4356] [4357] [4358] [4359] [4360] [4361] [4362] [4363] [4364] [4365] [4366] tirely of donor origin. Donor T cells were tolerant to host but not third party alloantigens as measured in vitro. In vivo, T-cell function appeared intact. Although most mice had lower levels of B-cell engraftment than T-cell engraftment, mice with ~1 0 % B cells were able to produce normal levels of IgM. Despite transplantation of fully allogeneic BM cells, stem cell engraftment could be demonstrated by secondary transfer of BM cells into lethally irradiated recipients that were congenic to the original in utero donor BM source. These data indicate that adult BM cells, even those fully allogeneic with the fetal recipient, can give rise to progeny with multilineage potential, which leads to restoration of Tcell and B-cell function. (at 24 weeks of gestation). The other, who received fetal liver and fetal thymus infusion at 26 weeks of gestation, had polymerase chain reaction (PCR) evidence of engraftment and subnormal T-cell function." These three cases illustrate both the potential clinical use and difficulties of in utero transplantation for the correction of SCID syndromes.
Recently, we have reported our findings'' in a murine in utero BM transfer model system of W4'/W4' fetal recipients with an endogenous stem cell defect due to a mutation in ckit (W locus).'o Fetal recipients homozygous for the W41 mutation (W4'/W4'), which results in a moderate anemia, were injected intraperitoneally on day 13/14 of a 21-day gestational period with nonmanipulated, adult congenic donor BM that differed from the fetal recipient at the glucose phosphate isomerase (Gpi-l) locus and Ly 5 (CD45) locus, a panhematopoietic determinant. Engrafted recipients had long-term chimerism, with almost 50% of T cells and 5% of B cells being of in utero donor BM origin. Stem cell engraftment was formally demonstrated by secondary transfer studies.
These data suggest that immune system replacement in nonanemic, immunodeficient mice may be achievable by in utero BM transfer. Therefore, we asked whether mice with SCID could be engrafted by in utero BM transfer under the same conditions used to generate donor T cells and B cells in W4'/W4' fetal recipients. It is possible that the partial reconstitution of T-and B-lineage cells by in utero BM transfer would require the recipient to have a defective stem cell system and would not occur in the setting of a normal stem cell number. However, W4'/W4' mice also have a functional deficit in their T-and B-cell Therefore, we wondered if the in utero transfer of nondefective BM cells into mice with a SCID disorder would result in engraftment limited to the lymphoid system. We also wondered if there would be a preferential engraftment of T-lineage cells as compared with B-lineage cells, as was observed in W4'/W4' fetal recipients.
This report provides information on the in utero correction of mice with SCID due to a DNA repair defect, a disorder also seen in humans with SCID. This type of SCID results in a failure of T-and B-cell antigen-specific receptor gene rearrangement, resulting in an absence or near absence of T-cell and B-cell number and Because Fleishman and Mintz" have shown that MHC (H-2) disparities between the adult donor BM cells and fetal recipient are infrequently associated with durable engraftment as compared with only minor histocompatibility disparities or no histocompatibility disparities (incidence, 6% to 9% U 32% to 44%, respectively), we initially examined the use of congenic BM. However, because human SCID fetal recipients will require allogeneic cells for in utero correction, the majority of our studies have focused on the use of allogeneic adult BM cells to most closely simulate a highly practical approach to in utero transfer in the United States. To our knowledge, these studies are the first to demonstrate that mice with classical SCID can be engrafted with either congenic or fully allogeneic hematopoietic cells and that engraftment can yield long-term lymphoid progeny with T-cell and B-cell function.
MATERIALS AND METHODS

Mouse Strains
B10.D2 (H-2d), C57BL/6 (H-2b), BI0.BR (H-2'), C.H-2h"''2 (designated bm12), and C.H-2hm' (designated bml) mice were purchased from Jackson Laboratories (Bar Harbor, ME). BALB/c (H-2d) mice were purchased from the National Institutes of Health (Bethesda, MD). C.B-l7 scidlscid (H-2", Ly S.I+, Gpi-l", BALB/c background genes) mice were purchased from Taconic (Germantown, NY). C57BLbLy 5.2'. Gpi-l" (H-2h, Gpi-l") mice were bred in our mouse colony by mating C57BW6-Ly 5.2' Gpi-l h mice with C57BL/ 6-Ly S.I+Gpi-l" mice.lY Progeny were screened by Gpi typing for Gpi-I" expression and by flow cytometry for Ly 5.2 and/or H-2 class I cell surface expression, as described below. Obligate heterozygotes were intercrossed to generate the desired homozygotes, which were doubly congeneic. C57BL/6Sz-scid/scid mice were provided by Dr Leonard Shultz (Jackson Laboratories).
A report of the immune function of these mice has been published.27 Control mice used for phenotypic and functional studies were 2 to 3 months of age.
In Utero Intraperitoneal Microinjections
BM cells were harvested from 6-to 12-week-old donors by flushing cells from the hind leg bones with phosphate-buffered saline (PBS). Cells were filtered through nylon mesh (Nitex HC3-41;
Tetko, Chicago, IL) to remove clumps before injection. For congeneic BM transfer. donor BM cells totaling 2 x I O h cells and 2 x 10' adult thymocytes from the same donor were suspended in a total volume of 3 pL for injection into each fetus. For allogeneic transfer experiments, 3.2 X IOh or 3.6 X 10' adult BM cells with or withoul 4 X 10' adult thymocytes, as indicated, from the same donor were suspended in 3 p L for injection into each CB-17 scidscid fetus. Pregnant females at day 1 3/ l 4 or 14/ 15 of a 2 1 -day gestation period were anesthetized with sodium pentobarbital injected intraperitoneally. The abdomen was entered with a midline ventral approach, and the uterine horns were exteriorized with jeweler's forceps. Cells were injected intraperitoneally through a Hamilton model 710 repeating syringe (Hamilton CO, Reno, NV) or with hand-drawn pipettes. The muscle layers were closed with nonabsorbable, synthetic 4-0 sutures, and metal surgical clips were used to close the skin.
Assessment oj" Engraftment
PB was screened at periodic intervals by Gpi typing and flow cytometry for evidence of in utero engraftment according to previously described procedures" and as detailed below. Heparinized PB from adult mice was obtained by retroorbital venipuncture under anesthesia. For Gpi typing to determine erythroid engraftment, whole blood lysates were used. For flow cytometry to determine T-cell, Bcell, and myeloid engraftment, PB was diluted in 3 mL of media and layered on ticoll (Histopaque I 119; Sigma, St Louis, MO), and the samples were centrifuged at 60013 for 30 minutes.
Gpi typing for etyrhroid engraftment.
PB was obtained from postnatal recipients at periodic intervals postnatally, beginning at I month after birth. A droplet of blood was collected on a piece of chromatography paper (Whatman 3030917; Hillsboro, OR). Whole blood was frozen at -20°C until analysis. The donor or recipient origin of the Gpi-I was assessed using starch gel electrophoresis, followed by transfer of whole blood lysates onto nylon membranes and then staining for Gpi isoenzymes as previously described." On each gel, whole blood lysates obtained from Gpi-l"' and Gpi-lh' strains were mixed together in ratios of I%:99%, 5%:95%, I0%:90%, 25%:7S%, and 50%:50%, respectively.
Flow qtornetry. PB cells or single-cell suspensions of BM, spleen. lymph node (LN), or thymus were prepared in buffer (PBS + 5% colostrum-free bovine serum + 0.015% sodium azide). Pelleted cells were incubated for IS minutes at 4°C with 0.4 pg of an anti-Fc receptor monoclonal antibody (MoAb; clone 2.462, provided by Dr Jay Unkless, Rockefeller University, New York, NY) to prevent Fc bindingzy Two-or three-color flow cytometry was performed using directly conjugated (fluoroscein isothyocyanate, phycoerythrin, or PerCP) MoAbs as previously described.'" Optimal concentrations of directly conjugated MoAbs were added to a total volume of 100 to 130 pL and incubated 1 and pan-granulocyte (clone Rb6-8C5, rat IgG2b).
All samples were analyzed on a FACscan (Becton Dickinson, Palo Alto, CA). Forward and 90" side-scatter were used to identify and gate PB cells with lymphocyte, monocyte, and granulocyte characteristics. A minimum of 10,000 events was examined. Background
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Analysis of Stem Cell Engrajhent
Stem cell engraftment was analyzed in vivo by secondary transfer experiments. Nonmanipulated adult BM, obtained from long-term chimeras that had been engrafted in utero at least 12 months earlier using adult BM cells, was used to repopulate lethally irradiated (9.0 Gy total body irradiation [TBI], delivered by x-ray as previously described3') congeneic (to the in utero donor strain recipients) mice. BM cells (3.5 X lo6) from individual donors were administered via tail vein to each of five secondary recipients. Post-bone marrow transplantation (BMT), these mice were analyzed for engraftment as discussed above. In vivo CD4' T-cell function was measured in long-term postnatal C57BL/6Sz-scid/scid chimeras injected with normal, congenic adult BM. These studies were performed by transferring either LN cells (IO6) or splenocytes (5 X lo6) intravenously into sublethally irradiated (6.0 Gy T B 1 by '37Cesium) bm12 recipients:' chosen to be MHC class I1 disparate with the in utero donor strain. When nontransplanted normal donors are used, the transfer of mature CD4+ T cells causes lethal graft-versus-host disease (GVHD) in bm12 recipients." In parallel, 1 X IO6 LN cells from the same postnatal chimeras were transferred into sublethally irradiated bml recipients, chosen to be MHC class I disparate with the in utero donor strain. Lethal GVHD results from the infusion of sufficient numbers of CD8+ T cells in this system?' Controls consisted of bm12 or bml recipients of irradiation alone or irradiation followed by the infusion of LN cells from nontransplanted C57BL/6 controls. The occurrence of GVHD symptomatology was monitored by thrice weekly quantitation of body weights and examination of recipients for clinical evidence of GVHD?' Mice were monitored daily for survival.
Postnatal Immune Function
In vivo B-cell function. To quantitate B-cell function without the requirement for the cooperation of CD4' T helper cells to assist in the switching from IgM to IgG production, circulating IgM levels were measured using the peroxidase-based colorimetric enzymelinked immunosorbent assay (ELISA) Dynatech Immulon4 (Chantilly, VA). The 96-well, flat-bottom plates were precoated for 2 hours at room temperature with a coating buffer containing 0.1 mom sodium bicarbonate and goat anti-mouse IgM (p-specific, Sigma; 0.4 pg per well). The fluid was removed, and the wells were washed three times with PBS. PBS + I % bovine serum albumin (BSA; Sigma) was then added to the wells for 1 hour at room temperature.
After washing the wells three times with PBS + 0.05% Tween-20, 100 pL of either diluted serum obtained from nontransplanted or in utero-injected postnatal recipients, mouse IgM standard (Rockland Laboratories, Gilbertsville, PA), or washing buffer (background control) was added to each well, and the mixture was incubated at room temperature for a period of 1 hour. The wells were aspirated free of fluid and washed three times with PBS + 0.05% Tween-20, and 100 p L of goat anti-mouse IgM (p-specific) peroxidase (Sigma) diluted 1:4,OOO in PBS + 0.25% BSA was added for 1 hour at room temperature. The wells were aspirated free of fluid and then washed in PBS + 0.05% Tween-20 three times. One hundred microliters of a freshly prepared solution containing 0-phenylenediamine dihydrochloride (Sigma; 10 mg tablet dissolved in 25 mL of a citrate buffer consisting of 0.126 g/mL citric acid + 0.1 1 g/mL anhydrous Na,HPO,, pH 5.0 + 0.0144% hydrogen peroxide) was added to each well, which was then incubated for 30 minutes at room temperature in the dark. One hundred microliters of 2 N H2S04 was used to stop the reaction. Colorimetric quantitation of the optical density of each well was read at 492-nm wavelength using a Biorad Model 2550 EIA reader (Biorad, Richmond, CA). Normal mice had values of ~5 0 0 pg/mL (range, 712 to 1,231 pglmL); and nonsuccessfully engrafted CB-17 scid/scid mice had values of 3.5 to less than 20 pglmL. Correlation coefficients for the standard curve were greater than 0.990 over an IgM range of 10 to 2,000 pglmL (the highest concentration tested).
RESULTS
Multilineage Engraftment in Postnatal C57BU6-scidhcid Recipients of I n Utero-Injected, Congenic, Adult Donor Lymphohematopoietic Cells
To establish the principle that the in utero injection of genetically normal adult BM cells is engraftable and could yield functional lymphoid cells, C57BL/6Sz-scid/scid recipients were injected with c57BU6-L~ 5.2+Gpi-la+ congenic adult BM (2 X lo6 cells) and adult congenic thymocytes (2 X lo5 cells). Of eight postnatal recipients screened for erythroid and leukocyte engraftment, one had evidence of both lineages of donor cells. Erythroid engraftment in this mouse steadily increased over time: 4 weeks and 6 weeks, 0%; 8 weeks, 1% to 5%; 12 weeks, 5% to 10%; 14 weeks, 10% to 25%; and 50 weeks postnatally, 50%. Leukocyte engraftment was examined on day 99 and day 253 postnatally, and the results are shown in Table 1 . Ninety-one percent (day 99) and 87% (day 253) of the PB cells were derived from the in utero donor source. All T-lymphoid (CD4' or CD87 and B-lymphoid (B220') lineage cells and 250% of granulocytes were derived from the in utero donor inoculum at both time periods.
Three-color flow cytometry was performed on splenocytes obtained on day 253 postnatally by elective splenectomy, as previously described.33 As compared with nontransplanted C57BU6 recipient, there was a similar constituency of both T-cell and B-cell subpopulations in the engrafted mouse (Table l). About two thirds of myeloid cells were of donor origin. A smaller number of splenocytes were present in the S-month-old in utero-engrafted C57BL16Sz-scidlscid spleen as compared with a 3-month-old normal control (37.2 x lo6 U 120 X IO6). Because all lymphoid cells were of in utero donor origin, there was no evidence of leakiness of the C57BL/6Sz-scid/scid mice with age.25,34,35 A C57BLl6Sz- scid/scid littermate mouse that received the same donor inoculum but had no evidence of PB leukocytes had a total of only 9.9 X IO' splenocytes, and no lymphoid cells were detectable. In vitro splenic proliferative responses of the engrafted C57BU6Sz-scid/scid mouse to four different types of allogeneic stimulators were comparable in magnitude but peaked earlier (on day 3 U day 4) as compared with the nontransplanted control (Fig 1) . Allogeneic responses in the C57BU6Sz-scidscid mouse that rejected the donor inoculum was severely depressed.
iNGRAFTED SClD NORMAL MOUSE
Day of Peak MLR ----Day
At 1 year after the in utero injection of donor cells, the engrafted C57BU6Sz-scid/scid mouse was electively killed for thymus, LN, and BM phenotyping. Thymocytes of the in utero-engrafted scid/scid mouse (age, 12 months) were entirely of in utero donor BM origin, undergoing normal maturation (Table l) , but were lower in total number as compared with a 3-month-old nontransplanted control (19 X 10' U 140 X lo'). All LN cells were of in utero donor BM origin. The T-cell compartment was phenotypically comparable with a nontransplanted control. There was a con- For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
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siderably lower proportion of LN B cells (9% U 25%) in the engrafted C57BW6Sz-scidscid mouse, even though the number of isolatable LN cells was not dramatically different (7 X lo6 U 13 X lo6; Table 1 ). There were also fewer BM B-cell precursors (3% U 29%, respectively), despite similar proportions of T cells and their precursors ( Table 1) . The myeloid compartment was almost exclusively of host origin in the in utero-engrafted mouse. As splenic B-cell proportions were comparable with those of controls when studied on day 158 postnatally, these data suggest that the Blymphoid cells declined in number over time and indicate that there is a preferential reconstitution of T-lymphoid as compared with either B-lymphoid or myeloid progenitor cells. (Table l) , secondary transfer studies were performed using BM from the engrafted C57BL/6Sz-scid/scid recipient to assess stem cell engraftment. BM (3.5 X lo6 cells) consisting of 13% cells derived from the in utero donor (c57BW6-L~ 5.2, Gpi-l") and 87% from the C57BLJ6Sz-scidscid fetal recipient (Ly 5.1+, Gpi-lb+) was infused into irradiated (9.0 Gy TBI) secondary C57BL/6 recipients (Ly 5.1+, Gpi-lb+). On day 54 post-BMT, none of the erythroid but 39% of PB leukocytes were derived from in utero-injected BM. PB leukocyte and erythroid engraftment analyzed at 4.5 months post-BMT was similar to the early time point. About 60% to 70% of CD4+ and CD8+ T cells in the PB, spleen, and LN were derived from the in utero donor BM. The thymus had too few cells to comprehensively evaluate in three of these four 8-monthold heavily irradiated recipients. Virtually all of the B cells in these organs were derived from the in utero donor BM ( Table 2 ). The total B-cell number in the spleen, LN, and BM (Table 2 ) was approximately one third to one half that observed in nontransplanted normal mice (data not shown). The partial B-cell reconstitution is also reflected by a relatively low number of splenocytes (18 x lo6) and isolatable LN cells (4.1 X lo6). The proportion of B cells in the PB at this time (21%) is just below the range observed in nontransplanted controls (22% to 36%). For unexplained reasons, the PB contained the lowest relative proportion of B cells derived from the in utero BM source. Of the myeloid cells in the PB and BM, 2% to 14% were from the in uteroinjected donor BM. These data indicate that T-cell and, to a lesser extent, B-cell and myeloid engraftment were durable in a C57BW6Sz-scidscid recipient of congenic lymphohematopoietic cells injected in utero. To assess in vivo CD4+ or CD8+ T-cell function, LN cells were harvested from the same BM donor as discussed above for transfer into sublethally irradiated bm12 (n = 5 ) or bml (n = 2) recipients, respectively (Fig 2) . The bm12 or bml recipients of LN cells (1 x 106/mouse) died 2 to 2.5 weeks post-BMT. Examination of the weight curves in these two groups of mice revealed a progressive post-BMT mean weight loss of 217.5% of their pre-BMT body weights, consistent with GVHD (data not shown). A similar time course was observed in this experiment when 1 X lo6 cells from nontransplanted C57BL/6 mice were infused under the same conditions. In contrast, sublethally irradiated bm12 (n = 4) or bml (n = 4) mice that did not receive LN injections had 75% and 100% 2-month actuarial survival rates, mean body weights exceeding pre-BMT weights by 1 month post-BMT, and no clinical symptomatology of GVHD. These studies demonstrate that mature CD4+ and CD8+ T cells developing from in utero transfer of BM cells into C57BL/ 6Sz-scidscid fetal recipients are functionally intact, as measured by the ability of these cells to cause GVHD-induced lethality. Because congenic BM is not a practical source of hematopoietic progenitor cells for the in utero correction of human fetuses with SCID, we sought to determine if allogeneic adult BM was a feasible alternative hematopoietic progenitor cell source. A series of seven separate experiments was performed in which C.B-17-scidscid (H-2d) fetal recipients were injected with fully allogeneic C57BW6 (n = 5 ) or c57BW6-L~ 5.2 (n = 1) or B1O.BR (H-2k; n = 1) donor BM, with or without supplemental adult thymocytes from the same donor. Adult thymocytes were added to the BM inocula as a source of T cells, because these cells have been previously shown to be capable of facilitating engraftment36 and because we wished to simulate clinical situations in which fetal thymus has been coinfused along with hematopoietic progenitor cells into humans with immunodeficiency disorders." Despite the infusion of allogeneic BM cells (with or without thymocytes), none of the engrafted postnatal recipients had any evidence of GVHD manifestations either at birth or during the time period when the animal matured and the level of donor T-cell engraftment increased.
Stem Cell Engraftment in a Long
PB Engraftment in
The PB erythroid and leukocyte chimerism results are summarized in Table 3 . Fifteen of 54 (28%) C.B-17 scidscid postnatal recipients had detectable levels of PB leukocyte engraftment when first analyzed at 2 3 9 days postnatally. Four (mice 5 , 8, 9, and 14) had low levels (52%) of PB leukocyte engraftment, and each lost all evidence of engraftment by the time of next analysis at approximately 3 to 4 months of age. Eleven mice had persistent chimerism of varying degrees, with up to 76% donor leukocytes and 90% donor erythrocytes in the PB (mouse 12) on day 131 post-BMT. Seven mice with initial levels of PB donor leukocyte engraftment of 223% had eventual donor PB leukocyte chimerism levels >21%, and two (mice 6 and 10) had 4% or 11% donor cells, respectively, at the end of the study period. Two mice that initially had intermediate (mouse 13, 5%; mouse 2, l 1 %) donor PB leukocyte chimerism levels became low-level chimeras (8% and 2%, respectively) at the end of the study. There were no apparent features that distinguished mice that had decreasing PB engraftment from those that had either stable or increasing PB engraftment levels. However, when considering results in which 2 two mice had engrafted within a given experiment, engraftment stability was relatively similar, suggesting that the net result of the number of engraftable donor hematopoietic cells and the graft resistance capacity of the postnatal recipient were fairly constant in a given experiment.
An interesting feature of the engraftment decline is that at a given time in different mice, the level of donor T-cell engraftment may not always be indicative of either B-cell engraftment or eventual graft loss. In some mice, donor B cells are lost, while donor T cells are retained. For example, in two mice with a total PB donor T-cell content of approximately 10% at 2 to 3 months of postnatal age, the proportion of donor B cells (38% U less than 1%) and total leukocyte engraftment (84% U 11%) differed considerably (mice 12 and 10). When both were retyped about 2 months later, the latter mouse had only 3% circulating donor leukocytes, while the former had 76% and retained both donor B cell and T cells. In other situations, donor T-and B-cell engraftment declined concurrently, although B-cell loss was still more rapid than T-cell loss. For example, mouse 15 had 65% For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Abbreviation: Expt, experiment.
Fetal recipients injected on day 13/14 with 3.2 x 10' BM cells.
t Fetal recipients coinjected with BM cells (3.6 x 10' ) plus thymocytes (4 x lo5) from the same donor on day 14/15 of gestation.
* Fetal recipients coinjected with 3 x 10' BM on day 14/15 of gestation. § Increased, greater than 7% higher donor cell levels at last v first analysis; decreased, greater than 7% lower donor cell levels at last vfirst analysis; absent, no detectable donor cells; stable, less than 7% change in donor cell levels at last v first analysis. Table 4 , mouse 11) demonstrate that PB donor of other recipients in these categories (Table 3) . These mice B cells may be more easily lost than donor T cells. were selected because each had similar initial donor PB For the purposes of illustration, we will discuss in more leukocyte engraftment (30%, 26%, and 23%, respectively) detail the PB engraftment results of three C.B-17-scidscid and were studied at both earlier (46 to 69 days) and later PB leukocyte engraftment in three selected C.B-l7-scid/scid fetal recipients from Table 3 to represent the spectrum of engraftment stability when compared with earlier (days 46 to 69) postnatal analysis, a time at which mice had similar levels of engraftment (mouse 1, 30%; mouse 10,23%; mouse 11. 24%). As compared with the earlier time points, these mice represent increasing (mouse 1: 30% H-2'+), decreasing (mouse 10: 23% H-Zb+). or stable (mouse 11: 24% H-Zb+) levels of engraftment. PB leukocytes were analyzed for B-cell (B220+), T-cell (CD4' or CD8'). and myelomonocytic (granl') engraftment by two-color flow cytornetry with anti-H-Zb (donor) and lineage-specific antibodies directly conjugated to fluorochromes. The percent of PB cells coexpressing donor and a given lineage marker is listed. Mice were studied earlier and later postnatally.
(131 to 173 days) times postnatally. As shown in Table 4 , despite the similar initial donor PB leukocyte engraftment percentages, substantial differences in the long-term chimerism state were noted. These and other data (eg, mouse 6) indicate that engraftment stabilization in this model system may require greater than 3 months of observation in some mice given allogeneic in utero transplantation, suggesting either that the number of engrafted stem cells may be somewhat limited or the host may develop over time the capacity to resist the continued presence of allogeneic stem cells. To determine if fully allogeneic, adult BM cells engrafted in utero were multipotential, representative long-term chimeras (postnatal days 127 to 250) were electively killed for flow cytometry and adoptive transfer studies. Three longterm C.B-17-scidscid recipients of C57BW6 BM cells (3.6 X IO6) without (mice 1 and 3) or with (mouse 4) supplemental thymocytes were studied for multiorgan system engraftment. These mice had increasing (mice 1 and 3) or stable (mouse 4) levels of PB engraftment at the time of last PB analysis (Table 3 ). Both C.B-17-scidscid recipients with increasing but comparable levels of PB donor cells (70%, 61 %) had similar overall levels of splenic engraftment (53%, 55%; Table 5 ). TCR a/@+, CD4+, and CD8+ cells originated exclusively from donor BM cells and attained similar proportions as the control mice ( Table 5 ). B cells also were derived exclusively from the in utero donor BM cells, reaching levels of approximately 30% to 50% of control mice ( Table 5) . Total splenic cellularity in the engrafted mice appeared to be reduced by 40% to 60%, paralleling the partial donor Bcell reconstitution. A minority (0 to 25%) of myelomonocytic cells were derived from the donor BM strain. In the in utero-engrafted mouse that had a lower but stable level of PB engraftment (mouse 4), T-cell number was slightly reduced as compared with the control, while the B-cell compartment remained entirely deficient. Splenic cellularity was only 12% that of the control mouse.
Multiorgan System Engraftment in
When examining the BM compartment, which is comprised primarily of nonlymphoid lineages, the three engrafted mice were found to have only low donor cell percentages ( 1 % to 5%) with a relatively high level of T-lineage, 0 to 1 1% B-cell lineage, and 0 to 3% myeloid cell reconstitution (Table 5 ). Overall BM cellularity was comparable with controls. Based on the data from PB, spleen, and BM typing, there was no discernible advantage to alloengraftment when comparing results obtained in the same experiment in which C.B-17-scidscid mice were injected with the same donor BM alone or with 4 X 10' supplemental adult thymocytes.
On day 250 postnatally, thymus and LN engraftment was examined in the C.B 1 -7-scidscid recipient that had the highest level of PB and BM engraftment (mouse l ) . The thymus in this relatively old (250 days of age) recipient contained 16 X 10' cells and a normal distribution of immature CD4 '8' (73%) and mature CD3e'CD4+8-(12%) and CD3t'4-8' (6%) cells as compared with the normal control mouse concurrently analyzed. The LN had only donor lymphoid cells present, with the proportion of T cells being somewhat higher than in a normal control mouse (TCR a/ p': 79% U 67%). This relative increase in T cells was due primarily to an increase only in the proportion of CD8' (36% U 26%) but not CD4' cells (38% U 40%), along with a decrease in donor B-lineage cells (15% U 32%). Overall. 92% of the LN cells were of donor origin, and 3% (all myelomonocytic cells) were of host origin. These data indicate that it is possible to achieve a high level of central (thymic) and peripheral (spleen, LN, PB) T-cell engraftment, with a more modest level of B-cell engraftment in the spleen, BM, PB, and LN.
T-cell und B-Cell Function in Long-Term C.B-17-scidscid Recipients of In Utero-Injected, Fully Allogeneic, Adult Donor Lymphohematopoietic Cells
To assess T-cell function, splenocytes from the two mice (mice 1 and 4) with the high levels of splenic donor cell engraftment (69% and 22%, respectively, Table 5 ) were analyzed on day 250 or 127 postnatally, respectively, in an MLR assay using several types of allogeneic stimulator cells (Fig  3A and B) . Splenic proliferative responses to B1O.BR were reproducibly higher than in controls, while responses to bm12 were more variable. In utero-engrafted recipients appeared to be tolerant of host-type H-2d+ stimulator cells. These data indicate that the T cells derived from the in utero donor BM graft were tolerant of donor and host alloantigens but fully reactive and sometimes even hyperreactive to third party alloantigens.
In vivo CD4+ T-cell function was measured in the recipient with the highest level of donor T-cell splenic reconstitution by transferring 2 X IO6 LN cells into sublethally irradiated bm12 recipients (n = 6). All succumbed to GVHD-induced lethality between days 13 and 16 post-BMT. These data indicate that For personal use only. on October 3, 2017. by guest www.bloodjournal.org From On the indicated postnatal day, postnatal recipients from Table 3 were electively killed for determination of multiorgan system engraftment by two-color flow cytornetry with anti-H-2b and lineage-specific antibodies directly conjugated to fluorochromes. Total cellularity is listed. The percent of cells coexpressing H-2b and a given lineage marker is listed. A nontransplanted C57BU6 control was also killed to determine the proportion of cells in each organ expressing the particular lineage-specific cell surface determinant.
donor BM-derived T cells are tolerant to host but not third party alloantigens, as measured by in vitro proliferative responses, and are sufficiently immunocompetent to mediate GVHD-induced lethality when adoptively transferred in vivo to a third party, MHC class II-disparate recipient.
B-cell function was measured by quantitating circulating IgM levels. Five of ten C.B-17-scidlscid recipients of fully allogeneic BM had circulating IgM levels greater than 500 pg/mL when analyzed 4 to greater than 6 months postnatally. Four of the five mice with IgM levels greater than 500 pgl mL had 8% donor PB B cells, while the fifth had 1%. This last mouse had higher overall levels of engraftment when phenotyped 2 months earlier (16% U 8%), although no lineage analysis was available at that time. Thus, IgM production may have been reflective of a time period when higher numbers of B cells were present. For the mice with very low IgM levels (~2 0 pg/mL), each had less than 1% PB donor B cells at all time periods studied. These data indicate that B cells can function to produce IgM when fully allogeneic donor cells engraft in utero.
Stem Cell Engraftment in Long-Term (24 months postnatally) C57BU6-scidscid Recipients of In UteroInjected, Fully Allogeneic, Adult Donor Lymphohematopoietic Cells
To assess stem cell reconstitution from in utero injections, BM (3 X lo6 cells containing 5% [1.5 X lo'], 2% (6 X lo4), and 1% (3 X 104) donor cells, respectively) from the three long-term in utero-engrafted recipients assessed for multiorgan system engraftment was adoptively transferred into secondary recipients (n = 5 for each individual donor). Secondary recipients were chosen to be c57BW6-L~ 5.2, so that these mice would be congenic to the in utero donor strain and, therefore, would be distinguishable by flow cytometry from both the in utero donor strain (c57BW6-L~ 5.1+) and the C.B-17-scidhcid (H-2d+) postnatal recipient using fluorochrome anti-H-2-specific and anti-Ly 5 alleleic MoAbs. Recipients were heavily irradiated (9.0 Gy TB1 by x-ray) to prevent rejection of the C.B-17-scidlscid component of the donor graft and minimize host cell reconstitution. In addition, the BM was not depleted of T cells or otherwise manipulated to optimize engraftment of the normal in utero donor and scid BM-containing inoculum of the primary re~ipient.~' Four of five secondary recipients per group survived the initial time and had PB phenotyping performed on days 54 to 78 post-BMT. Of 12 secondary recipients, 11 (92%) had PB cells derived from the in utero donor, although in nine of these secondary recipients, the percentages of in uteroderived donor BM cells were relatively low (1% to 5%). In the other two recipients (both derived from the primary recipient with 5% donor BM cells), 25% and 65%, respectively, of the PB was derived from the in utero donor BM. The stability of PB engraftment was measured on days 104 to 1 13 in the nine mice at that time. The proportion of PB cells derived from the in utero donor BM was stable. Specifically, six of seven (86%) mice had 1% to 3% engrafted cells (n = 6) as compared with 1% to 5% in earlier studies, with the remaining mouse having barely detectable (0.5%) donor cells. These data indicate that the in utero donor hematopoietic source could yield long-term reconstituting PB leukocytes in similar proportions as the BM that was used to rescue these irradiated secondary recipients.
On day 113 postsecondary BMT, multilineage PB and multiorgan system phenotyping studies were performed on three secondary recipients of BM from mouse 1 ( Table 6 ). CD4+ and CD8+ T-cell reconstitution were variable, with 15% to 75% (mean, 48%) and 17% to 4 4 % (mean, 31%) of these cells, respectively, derived from the in utero donor BM source. In two of the three mice, B cells were mostly (75% to 98%) of in utero donor BM origin, with the remaining mouse having few total B cells derived equally from both donor BM sources. This latter mouse appears to have rejected the in utero donor BM graft. The total proportion of B cal issue is whether sufficient T-and/or B-cell immune function could be restored so as to provide a long-lasting protection of the recipient from the consequences of a defective immune system. Thus, the major finding in our study is that the in utero injection of either congenic or fully allogeneic, nonmanipulated adult BM into SCID recipients yielded a functional T-cell and B-cell immune system that in some mice persisted for prolonged periods of time (greater than 4 months postnatally). In humans, this issue remains largely unresolved because of the complexities of the transplantation process used to reconstitute the SCID patient who has been most extensively analyzed, which involved infusions of lymphohematopoietic cells on two separate occasions from two different fetuses and an additional seven postnatal infusions using nine donors to speed immunologic reconstitution. Even though 10% of the PB lymphocytes were derived from in utero donor fetal liver cells by 1 month of age'5 and up to 26% were of donor origin at 1 year, one cannot easily segregate the effects of the in utero and postnatal infusions on the reconstitution of thymic and accessory cells needed for optimal reconstitution. Our data have demonstrated definitively that high and perhaps completely normal levels of mature CD4+ and CD8+ T cells derived from normal congenic or fully allogeneic adult BM cells can repopulate central and peripheral lymphoid organs and persist for prolonged periods of time. The mature CD4+ and CD8' T cells proliferated in vitro in response to alloantigens. In vitro, fetal recipients of fully allogeneic BM had a markedly deficient response to stimulator cells that express host-type H-2 determinants, suggesting that a state of donor anti-host cell tolerance had been induced."' The fact that a higher incidence of engraftment of live-born mice was seen with allogeneic mice versus congenic (13%) BM is interesting and might suggest that allogeneic BM-derived T cells favored the engraftment of hematopoietic progenitor cells, perhaps by eliminating competing host hematopoietic progenitor cells!'
If this is the case, we would need to hypothesize that insufficient numbers of BMderived post-thymic T cells were available to expand to the point where GVHD would occur in live-born mice. It is conceivable that some of the successfully engrafted fetal recipients experienced lethal GVHD before birth, because fetal scidscid recipients of allogeneic cells had a live-birth rate that was somewhat lower than recipients of non-GVHD-causing congeneic cells (40% U 55%, respectively). However, live-birth rates in both instances were comparable with our previous reports of 47% in W4'/W4' recipients of congeneic BM,'9 suggesting that the differences with allogeneic as compared with congenic BM are not due to in utero GVHD, and that BM is a relatively poor source of lethal GVHD even when administered to irradiated adult mice in these strain combinations. Moreover, in the live-born mice, because we could not find evidence of responses to host alloantigens in long-term chimeras, any alloreactive donor T cells transferred along with the donor BM graft would need to be present in very low numbers or be counterbalanced by newly repopulating T cells from donor hematopoietic progenitor cells that are tolerant to host alloantigens by virtue of their education process. In vivo, CD4' andor CD8+ T cells derived from the adult in utero BM source mediated a lethal GVHD response to allogeneic MHC class I1 or class I molecules, respectively, when transferred into secondary recipients, indicating that third-party reactivity was intact.
To our knowledge, only one study with direct relevance to our investigations, ie, directed toward correcting a severe immunodeficiency disorder, has been reported. In that study, the investigators transferred lymphohematopoietic cells in utero into fetal recipients with a primary immune d e f~t . 4~ Fetal recipients were transgenic mice homozygous for the human CD3-E transgene, which results in a defect in the thymic cortex and in T-cell development at the earliest stage of T-lineage commitment. In utero transplantation was shown to restore the thymic cortex and allow T-cell maturation. However, quantitative data on the function of mature T cells were not provided. Previous reports of in utero-transplanted normal or W-mutant mice have primarily focused on the rejection of skin grafts.8s28s44 Skin graft tolerance and donor allotypic immunoglobulin production have been observed. However, skin graft acceptance alone does not indicate the presence of a high level of donor lymphoid cell ~h i r n e r i s r n . '~~~~~' Conversely, skin graft rejection does not indicate that chimerism is absent. For example, bovine twins that are naturally chimeric due to intrauterine blood exchanges can be tolerant of BM cells but not skin grafts from For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 4364 BLAZAR, TAYLOR, AND VALLERA the other twin.7 Therefore, tolerance may be tissue-specific. Consistent with this notion are studies in mice demonstrating the existence of skin-specific antigens48 and other studies showing that solid organs can be rejected in sheep that had evidence of 3% to 5% BM lymphoid chimerism. Data on the postnatal acquisition of tolerance to fully allogeneic lymphoid cells as measured in vivo by assays other than skin graft rejection are available in one study in which the in utero injection of F1 hybrid BM cells into parental strain fetal rats was tested. In some instances, postnatal recipients manifested a specific reduction in the graft-versus-host response (GVHR) as measured by a localized (popliteal LN) GVHR assay.I4 These rats were also skin graft-tolerant. It will be of interest to determine whether the mechanism(s) of T-cell tolerance induction after in utero administration of fully allogeneic BM cells differs from or postnatal tolerance ind~ction,~' in which persistent chimerism, as detectable by PB or splenic flow cytometry, may not be essential for the maintenance of tolerance. Neonatal tolerance in fact differs from adult tolerance induction by kinetics, requirements for chimerism, and most likely, cell types and mechanism(s) responsible for tolerance induction.47
As far as B-cell engraftment and function after following in utero lymphohematopoietic transfer is concerned, studies by Fleishman et ala have shown that donor allotypic immunoglobulin can be generated after in utero hematopoietic transfer; no information was reported on the level or location (eg, BM, spleen, LN) of B cells.44 In our studies, B-cell function in engrafted mice was found to be sufficiently intact such that long-term chimeras had normal IgM levels. Because no detectable host B-(or T-) cells were seen in the PB, BM, spleen, or LN (or thymus) of the mice examined, IgM production must have been derived from donor rather than host B cells, as has been observed in some human SCID patient^.^" Thus, despite the relatively old age of some of these recipients, l e a k i n e s~'~. '~~'~ was not observed in either the B-cell or T-cell compartments. Because IgM production is T-independent, additional studies will be necessary to examine T/B-cell cooperativity and other Ig subclasses. Such cooperativity is required for the generation of specific IgG antibody in response to antigenic challenge. In addition, for optimal response to foreign antigens, T cells also need to cooperate with macrophages and other antigen-presenting cells.49 It will be important to determine whether the T cells derived from in utero-reconstituted chimeras show a predilection for host MHC restriction, as seen when F1 cells (eg, [A X B] F1) are forced to mature in parental strain (A or B type) adult, irradiated recipient^.^"."
The final major issue addressed by our studies relates to the lineage of cells and the longevity of engraftment. Studies in mice and humans have shown, in general, that lineages with the greatest functional deficits (eg, erythroid in W4'/W4' micesz,53 or mice with beta thalassemias4 are at a competitive disadvantage to the infused donor cell inoculum and, therefore, are most easily replaced by BM-derived cells. Children with SCID syndromes who have a minimal or no detectable immune function can be infused with allogeneic sibling donor BM grafts without myelodblation. In these nonmyeloablated situations and in others when T cell-depleted, HLA-nonidentical donor BM is given to children with SCID along with conditioning regimens, T cells tend to engraft to a greater degree than B cells or monocyte lineage ~e l l s .~"~"~~~ Because only limited numbers of donor stem cells likely engraft even in W-mutant mice after in utero transfer of non-enriched adult BM cells given in the same cell dose range as used in the current study,"' we wondered whether the in utero infusion of adult BM would lead to transient engraftment of committed limited precursor cells or to the more desirable situation of stem cell engraftment. We anticipated that, in the latter situation, T-cell engraftment might be highest followed by B-cell and myeloid-cell engraftment, as is seen in human patients with SCID. Somewhat surprisingly, engraftment of lymphoid and nonlymphoid lineages occurred in the context of a normal hematopoietic system in scidscid fetal recipients. In general, the level of T-cell engraftment was superior to B-cell or myelomonocytic-cell engraftment.
We have been able to formally demonstrate that stem cell engraftment occurred after in utero congenic or allogeneic BM transfer. Although engraftment seemed to follow the same pattern as observed in humans (ie, T cells engrafted more efficiently than either B cells or myeloid cells, because the BM used for adoptive transfer was not depleted of the small number of T cells typically present in normal BM), we cannot exclude the possibility that a component of the T-cell engraftment in the secondary recipients was derived from postthymic BM T cells. Even though both the degree of engraftment and the durability of leukocyte engraftment were variable, a proportion of engrafted recipients were able to maintain high levels of multilineage engraftment such that the T-and B-lymphoid lineages and the majority of PB myeloid cells were of donor BM origin. If this did, indeed, occur. then engraftment of lineages other than T cells might be more reflective of true stem cell engraftment. In that regard, a curious finding of these studies has been the relatively low level of BM engraftment evident in recipients of congenic or allogeneic donor BM. We attribute this status to relatively poor erythroid and myeloid lineage engraftment. PB erythroid engraftment, with some exceptions, was not detectable at the level of sensitivity of Gpi typing. The BM has a large erythroid component, and in many mice, fewer donor than host myeloid cells were detectable in the BM and other organs. However, we cannot exclude the possibility that only a lymphoid stem cell engrafted. Secondary transfer studies then would show lymphoid engraftment without myeloid engraftment. However, inconsistent with this possibility is the fact that PB granulocytes, which have a short half-life, are present in long-term chimeras and secondary recipients. These latter data would require a hypothesis that a common lymphoid-myeloid progenitor cell or stem cell without erythroid-differentiating properties engrafted. No precedent exists for such a hypothesis. As an explanation for these data and the variable level of engraftment in the mice in this study, we favor the hypothesis that a low level of donor stem cell engraftment has occurred due to the limited number of stem cells actually infused into the fetus from the nonmanipulated adult BM source, as compared with the normal stem cell content of the host. Preferential central and peripheral repopulation by lymphoid cells could then account for the more substantial lymphoid engraftment with more
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From limited nonlymphoid engraftment. In instances in which multilineage engraftment was high in the nonlymphoid lineages, more donor stem cells were able to be engrafted.
In summary, we have been able to reconstitute mice with a SCID disorder due to a DNA repair defect by in utero transfer of congenic or fully allogeneic adult donor BM cells. Mice with high engraftment levels had T-cell and B-cell function as measured by in vitro and/or in vivo assays. Stem cell engraftment was formally shown by secondary transfer studies. These data provide an important forum for improving our understanding of the fine specificities and possible functional limitations of in utero transplantation of allogeneic BM cells into scidscid mice.
